What is SOPHiA GENETICS?
SOPHiA GENETICS operates at the intersection of artificial intelligence and genomic data analysis, providing a sophisticated platform that empowers clinicians and biopharmaceutical researchers. By transforming massive, complex datasets into clear diagnostic and therapeutic pathways, the company addresses critical challenges in the treatment of cancer and rare genetic disorders. Its market position is defined by a commitment to data-driven healthcare, enabling medical professionals to deliver more accurate, personalized patient care. Through its proprietary technology, the firm has become an essential partner for healthcare institutions seeking to modernize their diagnostic capabilities and improve patient outcomes on a global scale.
How much funding has SOPHiA GENETICS raised?
SOPHiA GENETICS has raised a total of $482.8M across 7 funding rounds:
Series A
$3M
Series B
$13.8M
Series C
$15M
Series D
$30M
Series E
$77M
Series F
$110M
Share Placement
$234M
Series A (2013): $3M, investors not publicly disclosed
Series B (2014): $13.8M led by Endeavour Vision and Swisscom Ventures
Series C (2015): $15M, investors not publicly disclosed
Series D (2017): $30M featuring Invoke Capital, Balderton Capital, and 360 Capital Partners
Series E (2019): $77M backed by Balderton Capital, Idinvest Partners, Generation Investment Management, and Alychlo
Series F (2020): $110M with participation from Credit Suisse, Eurazeo Growth, aMoon, Endeavor Vision, Generation Investment Management, Swisscom Ventures, Pictet Group, and Hitachi Ventures
Share Placement (2021): $234M, investors not publicly disclosed
Key Investors in SOPHiA GENETICS
Generation Investment Management
Generation Investment Management focuses on sustainable economic systems, mobilizing capital to address global challenges through strategic research and advocacy.
Endeavour Vision
Endeavour Vision is a specialized investment advisory firm that targets transformative healthcare technologies, including digital health and medical devices.
Swisscom Ventures
Swisscom Ventures is the investment arm of the Swiss telecommunications provider, focusing on high-growth technology sectors that align with digital infrastructure and innovation.
What's next for SOPHiA GENETICS?
With the support of its latest capital injection, SOPHiA GENETICS is poised to accelerate its expansion into new therapeutic areas and deepen its technological infrastructure. The company's strategic roadmap focuses on enhancing its AI-driven analytics to further reduce the time-to-insight for complex disease diagnosis. By leveraging its robust network of clinical partners and the backing of high-profile institutional investors, the firm is well-positioned to scale its operations, refine its precision medicine solutions, and continue its mission of driving positive global health impact through advanced data science.
See full SOPHiA GENETICS company page
